prediction of overall survival with 2nd line l2os chemotherapy ct in patients with advanced biliary tract cancer abtc ageo ct2bil cohort update and international multicenter external validations

n/

Analysis of BAC-end sequences in rainbow trout: Content characterization and assessment of synteny between trout and other fish genomes

<p>Abstract</p> <p>Background</p> <p>Rainbow trout (<it>Oncorhynchus mykiss</it>) are cultivated worldwide for aquaculture production and are widely used as a model species to gain knowledge of many aspects of fish biology. The common ancestor of the salmonids experienced a whole genome duplication event, making extant salmonids such as the rainbow trout an excellent model for studying the evolution of tetraploidization and re-diploidization in vertebrates. However, the lack of a reference genome sequence hampers research progress for both academic and applied purposes. In order to enrich the genomic tools already available in this species and provide further insight on the complexity of its genome, we sequenced a large number of rainbow trout BAC-end sequences (BES) and characterized their contents.</p> <p>Results</p> <p>A total of 176,485 high quality BES, were generated, representing approximately 4% of the trout genome. BES analyses identified 6,848 simple sequence repeats (SSRs), of which 3,854 had high quality flanking sequences for PCR primers design. The first rainbow trout repeat elements database (INRA RT rep1.0) containing 735 putative repeat elements was developed, and identified almost 59.5% of the BES database in base-pairs as repetitive sequence. Approximately 55% of the BES reads (97,846) had more than 100 base pairs of contiguous non-repetitive sequences. The fractions of the 97,846 non-repetitive trout BES reads that had significant BLASTN hits against the zebrafish, medaka and stickleback genome databases were 15%, 16.2% and 17.9%, respectively, while the fractions of the non-repetitive BES reads that had significant BLASTX hits against the zebrafish, medaka, and stickleback protein databases were 10.7%, 9.5% and 9.5%, respectively. Comparative genomics using paired BAC-ends revealed several regions of conserved synteny across all the fish species analyzed in this study.</p> <p>Conclusions</p> <p>The characterization of BES provided insights on the rainbow trout genome. The discovery of specific repeat elements will facilitate analyses of sequence content (e.g. for SNPs discovery and for transcriptome characterization) and future genome sequence assemblies. The numerous microsatellites will facilitate integration of the linkage and physical maps and serve as valuable resource for fine mapping QTL and positional cloning of genes affecting aquaculture production traits. Furthermore, comparative genomics through BES can be used for identifying positional candidate genes from QTL mapping studies, aid in future assembly of a reference genome sequence and elucidating sequence content and complexity in the rainbow trout genome.</p

Associations between Nitric Oxide Synthase Genes and Exhaled NO-Related Phenotypes according to Asthma Status

International audienceBACKGROUND: The nitric oxide (NO) pathway is involved in asthma, and eosinophils participate in the regulation of the NO pool in pulmonary tissues. We investigated associations between single nucleotide polymorphisms (SNPs) of NO synthase genes (NOS) and biological NO-related phenotypes measured in two compartments (exhaled breath condensate and plasma) and blood eosinophil counts. METHODOLOGY: SNPs (N = 121) belonging to NOS1, NOS2 and NOS3 genes were genotyped in 1277 adults from the French Epidemiological study on the Genetics and Environment of Asthma (EGEA). Association analyses were conducted on four quantitative phenotypes: the exhaled fraction of NO (Fe(NO)), plasma and exhaled breath condensate (EBC) nitrite-nitrate levels (NO2-NO3) and blood eosinophils in asthmatics and non-asthmatics separately. Genetic heterogeneity of these phenotypes between asthmatics and non-asthmatics was also investigated. PRINCIPAL FINDINGS: In non-asthmatics, after correction for multiple comparisons, we found significant associations of Fe(NO) levels with three SNPs in NOS3 and NOS2 (P ≤ 0.002), and of EBC NO2-NO3 level with NOS2 (P = 0.002). In asthmatics, a single significant association was detected between Fe(NO) levels and one SNP in NOS3 (P = 0.004). Moreover, there was significant heterogeneity of NOS3 SNP effect on Fe(NO) between asthmatics and non-asthmatics (P = 0.0002 to 0.005). No significant association was found between any SNP and NO2-NO3 plasma levels or blood eosinophil counts. CONCLUSIONS: Variants in NO synthase genes influence Fe(NO) and EBC NO2-NO3 levels in adults. These genetic determinants differ according to asthma status. Significant associations were only detected for exhaled phenotypes, highlighting the critical relevance to have access to specific phenotypes measured in relevant biological fluid

A compact kinetic inductance travelling wave parametric amplifier with continuous periodic loading structure

Travelling wave parametric amplifiers (TWPAs) made from highly non-linear reactive superconducting thin films have been demonstrated to be a potentially viable quantum-noise-limited amplifier technology for various fundamental physics platforms, including microwave/mm/sub-mm astronomy, dark matter search experiments, neutrino mass experiments, and qubit readout. We present a kinetic inductance TWPA consisting of a patterned titanium nitride film on a sapphire substrate, which comprises a coplanar waveguide (CPW) with a continuous, smoothed periodic loading (PL) structure that modulates the characteristic impedance of the CPW in a double sinusoidal fashion. This double sinusoidal modulation creates much stronger dispersion features than a conventional PL design, which allows for phase matching and pump harmonic suppression over a much shorter transmission length, potentially leading to reduced losses. In this paper, we shall discuss in detail the design of our TWPA and present the predicted gain-bandwidth characteristics from electromagnetic simulations

PIPAC--Chimiothérapie intrapéritonéale vaporisée. Un traitement innovateur de la carcinose péritonéale [PIPAC--Pressurized intraperitoneal aerosol chemotherapy. A novel treatment for peritoneal carcinomatosis]

La carcinose péritonéale (CP) demeure un défi diagnostique aux options thérapeutiques limitées. L’effet de la chimiothérapie systémique reste limité pour le péritoine en raison d’une faible pénétration et d’une résistance nodulaire. La chimiothérapie hyperthermique intrapéritonéale (CHIP) prolonge la survie de patients sélectionnés mais comporte une incidence de complications élevée.La chimiothérapie intrapéritonéale vaporisée (PIPAC) disperse les agents à l’intérieur de la cavité péritonéale par laparoscopie. La distribution et la pénétration dans les tissus sont supérieures à la chimiothérapie systémique et à la CHIP à plus faibles doses. Les effets secondaires systémiques et le traumatisme chirurgical sont limités. Les taux de réponses histologiques et cliniques chez des patients résistant aux platines approchent les 70% et la survie semble être améliorée en comparaison aux thérapies standards. [Peritoneal carcinomatosis remains a diagnostic challenge with sparse treatment options. The effect of systemic chemotherapy remains limited inside the peritoneum due to low penetration and a relative resistance of peritoneal nodules. Heated IntraPeritoneal Chemotherapy (HIPEC) improves survival in selected patients but entails a high incidence of complications. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) allows to disperse the active agents inside the peritoneal cavity by laparoscopy. Distribution and tissue penetration of chemotherapy by PIPAC are superior to HIPEC and systemic chemotherapy despite of lower doses. Systemic side effects are uncommon and surgical trauma is limited. Histological and clinical response rates in platinum-resistant patients approach 70% and survival data appear to be favorable compared with standard therapy.]]]> Aerosols; Antineoplastic Agents/administration &amp; dosage; Humans; Laparoscopy; Peritoneal Neoplasms/drug therapy; Peritoneal Neoplasms/surgery; Pressure fre oai:serval.unil.ch:BIB_18041BA3DE72 2022-01-01T02:12:02Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_18041BA3DE72 Pour une anthropologie historique des récits héroïques grecs : analyse structurale et pragmatique poétique des "mythes" Calame, C. info:eu-repo/semantics/article article 2013 Europe, no. 91, pp. 147-169 info:eu-repo/semantics/altIdentifier/pissn/0014-2751 fre oai:serval.unil.ch:BIB_18042 2022-01-01T02:12:02Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_18042 Pairing of Vß6 with certain V&lt;Font face="Symbol"&gt;a&lt;/Font&gt;2 family members prevents T cells deletion by &lt;I&gt;Mt&lt;/I&gt;v-7 superantigen. Aude-Garcia, C Attinger, A Housset, D MacDonald, HR Acha-Orbea, H Marche, PN Jouvin-Marche, E info:eu-repo/semantics/article article 2000 Molecular Immunology, vol. 37, pp. 1005-1012 oai:serval.unil.ch:BIB_1804FCE0ED5F 2022-01-01T02:12:02Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_1804FCE0ED5F Erratum: Present Status of Musculoskeletal Radiology in Europe: International Survey by the European Society of Musculoskeletal Radiology (ESSR). info:doi:10.1055/s-0040-1722564 info:eu-repo/semantics/altIdentifier/doi/10.1055/s-0040-1722564 info:eu-repo/semantics/altIdentifier/pmid/33348416 Snoj, Ž. Hebar, T. Sconfienza, L.M. Vanhoenacker, FMHM Shahabpour, M. Salapura, V. Isaac, A. Drakonaki, E. Vasilev, Y. Drape, J.L. Adriaensen, M. Friedrich, K. Guglielmi, G. Vieira, A. Sanal, H.T. Kerttula, L. Hellund, J.C. Nagy, J. Heuck, A. Rutten, M. Tzalonikou, M. Hansen, U. Niemunis-Sawicka, J. Becce, F. Silvestri, E. Juan, ELS Wörtler, K. info:eu-repo/semantics/article article 2020-06 Seminars in musculoskeletal radiology, vol. 24, no. 3, pp. e1 info:eu-repo/semantics/altIdentifier/eissn/1098-898X urn:issn:1089-7860 eng oai:serval.unil.ch:BIB_17FB243E7258 2022-01-01T02:12:02Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_17FB243E7258 Detection of yeasts and filamentous fungi in blood cultures during a 10-year period (1972 to 1981) info:eu-repo/semantics/altIdentifier/pmid/7153348 Bille, J. Stockman, L. Roberts, G. D. info:eu-repo/semantics/article article 1982-11 Journal of Clinical Microbiology, vol. 16, no. 5, pp. 968-70 info:eu-repo/semantics/altIdentifier/pissn/0095-1137 <![CDATA[During a 10-year period (January 1972 to December 1981), 69,066 fungal blood cultures were performed by using a biphasic brain heart infusion medium. A total of 838 fungi were recovered from 302 patients. Candida species represented 71% (595) of all positive cultures, Cryptococcus neoformans 12.6% (106), and Histoplasma capsulatum 13.1% (110)

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

BACKGROUND: Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODS: In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTS: A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval [CI], 0.78 to 1.39; P=0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONS: In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.)

Design of Near Infrared and Visible Kinetic Inductance Detectors Using MIM Capacitors

We are developing superconducting Microwave Kinetic Inductance Detectors to operate at near infrared and optical wavelengths for astronomy. In order to efficiently meet with the requirements of astronomical applications, we propose to replace the interdigitated capacitor by a metal, insulator, metal capacitor which has the advantage of presenting a larger capacitance value within a much smaller space. The pixel will occupy a space of typically 100 micrometers by 85 micrometers which is nine times less than a typical pixel size using the interdigitated capacitor operating at the same frequency, below 2 GHz

Importance of infarct size versus other variables for clinical outcomes after PPCI in STEMI patients

Despite promising experimental studies and encouraging proof-of-concept clinical trials, interventions aimed at limiting infarct size have failed to improve clinical outcomes in patients with ST-elevation myocardial infarction (STEMI). Our objective was to examine whether variables (cardiovascular risk factors, comorbidities, post-procedural variables, cotreatments) might be associated with clinical outcomes in STEMI patients independently from infarct size reduction. The present study was based on a post hoc analysis of the CIRCUS trial database (Clinicaltrials.gov NCT01502774) that assessed the clinical benefit of a single intravenous bolus of cyclosporine in 969 patients with anterior STEMI. Since cyclosporine had no detectable effect on clinical outcomes as well as on any measured variable, we here considered the whole study population as one group. Multivariate analysis was performed to address the respective weight of infarct size and variables in clinical outcomes. Multivariate analysis revealed that several variables (including gender, hypertension, renal dysfunction, TIMI flow grade post-PCI \textless 3, and treatment administered after PCI with betablockers and angiotensin-converting enzyme inhibitors) had per se a significant influence on the occurrence of [death or hospitalization for heart failure] at 1 year. The relative weight of infarct size and variables on the composite endpoint of [death or hospitalization for heart failure] at 1 year was 18% and 82%, respectively. Several variables contribute strongly to the clinical outcomes of STEMI patients suggesting that cardioprotective strategy might not only focus on infarct size reduction